(lp0
S"Company Update : MannKind Corporation Announces Q4 and Full Year ... Smarter Analyst - Mar 16, 2017 Shares of MannKind closed today at $2.07, up $0.05 or 2.48%. MNKD has a 1-year high of $11.20 and a 1-year low of $1.74. The stock's 50-day moving average is $0.93 and its 200-day moving average is $0.69.MannKind Corporation  Moves Higher on Volume Spike for March 17 - Equities.com"
p1
aS"Here's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February Motley Fool - Mar 7, 2017 Shares of MannKind , a biopharmaceutical company primarily focused on the treatment of diabetes, plummeted 24% in February, according to data from S&amp;P Global Market Intelligence."
p2
aS'Why MannKind Corporation Stock Is Sinking Today Motley Fool - Mar 3, 2017 MannKind Corp.  is having yet another bad day today, with its stock falling 19% as of 11:30 a.m. EST on Friday.MannKind Corporation  Stock Sinks on Reverse Stock Split Plans - Investorplace.comMannKind Corporation  Plunges 12.78% on March 03 - Equities.com'
p3
aS"MannKind Corporation and Charles Mattocks Announce REVERSED-America's First ... GlobeNewswire  - Mar 8, 2017 VALENCIA, Calif. and TAMPA, Fla., March 08, 2017  -- MannKind Corporation and Bella &amp; Elle Media LLC announce MannKind's sponsorship of Reversed, a production series aimed at educating the show's participants and viewing&nbsp;..."
p4
aS"MannKind Corporation  Delivered A Better ROE Than The Industry, Here's Why Simply Wall St - Mar 16, 2017 MannKind Corporation  delivered 113% ROE in the last year. However, to put MannKind's Return on Equity in perspective, we must compare it to the performance of its industry, which averaged an ROE of 27.46%."
p5
aS'MannKind - Afrezza Sales Struggle As February Comes To A Close Seeking Alpha - Mar 6, 2017 MannKind  investors hope that the third sales force pushing Afrezza is the charm, but the probabilities are stacked against them.'
p6
aS'Better Buy: MannKind Corp. vs. Dexcom Motley Fool - Mar 9, 2017 MannKind  and Dexcom  are two such businesses. Both companies have launched innovative products that are designed to make it far easier for patients to manage their disease.'
p7
aS"MannKind's  CEO Matt Pfeffer Presents At 29th Annual ROTH Conference ... Seeking Alpha - Mar 14, 2017 Okay. We are going to move onto our next presentation from MannKind Corporation. Ticker, MNKD. An approximately $200 million market cap company that is focused on drug delivery and treatments for diabetes."
p8
aS'MannKind: Empty Saddles And Empty Promises Seeking Alpha - Feb 27, 2017 ... of 10%, where achieving this microscopic incremental revenue increase, MannKind  will need years and maybe decades before they could ever achieve a break-even point with revenues showing a profit for this floundering corporation.Shares of MannKind Corporation  Plunge -2.26% - Energy IndexTo Buy Or Sell MannKind Corporation  On Latest Analyst Consensus - Fiscal Standard'
p9
aS"Two Biotechs To Watch This Week: Novan, Inc.  and MannKind ... Market Exclusive - Mar 6, 2017 Last week we saw plenty of volatility across the healthcare and biotechnology sectors, driven both by macro and micro factors. We're expecting much of the same this week, and so as we kick off a fresh session, here are two companies that could really ..."
p10
a.